Compare Dyne Therapeutics Inc. Common Stock (DYN) vs iShares MSCI Japan ETF (EWJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs iShares MSCI Japan ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while iShares MSCI Japan ETF trades at $94.8 (market cap $23.55B). The key difference: iShares MSCI Japan ETF is far larger — about 8.2× Dyne Therapeutics Inc. Common Stock's market cap, and iShares MSCI Japan ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and iShares MSCI Japan ETF for 57 Days on average.
| DYN | EWJ | |
|---|---|---|
Market Cap | $2.86B | $23.55B |
Volume | 3,341,579 | 1,896,806 |
Sector | Health | Broad Market / Factor |
52-Week High | $26.78 | $99.32 |
52-Week Low | $14.60 | $79.49 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
EWJ, the iShares MSCI Japan ETF, trades at $97.32 with no significant daily movement. Technical indicators show a bullish overall signal with moving averages supporting upward momentum, while oscillators remain neutral. The ETF benefits from Japan's economic developments including recent Bank of Japan rate hikes and fiscal stimulus measures. Support and resistance levels cluster tightly around the current price, indicating potential for breakout movement.
The outlook for EWJ appears cautiously optimistic as Japan navigates monetary policy normalization while maintaining growth stimulus. Investment opportunities include exposure to Japan's AI and semiconductor sectors, though risks persist from yen volatility, rising bond yields, and global macroeconomic pressures. The ETF's performance relative to the S&P 500 in 2026 suggests international diversification benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →
